Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B

Hepatology

Volumn 64, Issue 5, 2016, Pages 1507-1517

  Cheng, Jenny Yeuk Ki ^a   Wong, Vincent Wai Sun ^a   Tse, Yee Kit ^a   Chim, Angel Mei Ling ^a   Chan, Henry Lik Yuen ^a   Wong, Grace Lai Hung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC HEPATITIS B; CLINICAL OUTCOME; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RISK ASSESSMENT; TRANSIENT ELASTOGRAPHY; CARDIOVASCULAR DISEASES; COMPLICATION; LIVER DISEASES; MORTALITY; RISK FACTOR;

CARDIOVASCULAR DISEASES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER DISEASES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84992446011     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28778     Document Type: Article

References (31)

1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546–1555.
2. Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537–1547.
3. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006;26:153–161.
4. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. http://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/. Published March 2015. Accessed May 28, 2016.
5. Lo AO, Wong GL. Current developments in nucleoside/nucleotide analogues for hepatitis B. Expert Rev Gastroenterol Hepatol 2014;8:607–622.
6. Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409–415.
7. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009;58:111–117.
8. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388–1402.
9. Liaw YF, Kao JH, Piratsivuth T, Gane E, Han KH, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531–561.
10. Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002;68:182–187.
11. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261–283.
12. Lo AO, Wong VW, Wong GL, Chan HY, Cheung CM, Chan HL. Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine. Antivir Ther 2013;18:671–679.
13. Wong GL, Wong VW, Choi PC, Chan AW, Chum RH, Chan HK, et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol 2008;6:1027–1035.
14. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011;4:363–371.
15. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022.
16. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870–947.
17. Andrus B, Lacaille D. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol 2014;63:2886.
18. Marshall A, Altman DG, Royston P, Holder RL. Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study. BMC Med Res Methodol 2010;10:7.
19. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 2013;32:3388–3414.
20. Fu SC, Huang YW, Wang TC, Hu JT, Chen DS, Yang SS. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study. Aliment Pharmacol Ther 2015;41:1200–1209.
21. Xu X, Su Y, Song R, Sheng Y, Ai W, Wu X, et al. Performance of transient elastography assessing fibrosis of single hepatitis B virus infection: a systematic review and meta-analysis of a diagnostic test. Hepatol Int 2015;9:558–566.
22. Wong GL, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol 2014;60:339–345.
23. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113–1132.
24. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010;59:1410–1415.
25. Christiansen KM, Mossner BK, Hansen JF, Jarnbjer EF, Pedersen C, Christensen PB. Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study. PLoS One 2014;9:e111912.
26. Lau CC, Sun T, Ching AK, He M, Li JW, Wong AM, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell 2014;25:335–349.
27. Kuo YH, Lu SN, Chen CH, Chang KC, Hung CH, Tai WC, et al. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS One 2014;9:e93160.
28. Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination. J Gastroenterol Hepatol 2013;28:1842–1848.
29. Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination. J Gastroenterol Hepatol 2013;28:1762–1769.
30. Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 2014;39:883–893.
31. Wong GL, Chan HL, Chim AM, Wong VW. Liver fibrosis progression, new-onset metabolic syndrome and risk of hepatocellular carcinoma in chronic hepatitis B—an 8-year prospective cohort study of 1,178 patients with paired transient elastography examination. Hepatology 2015;62:965A.